Evidence map›Paper›PMID 28440344›Full record

ArticleThe pharmacogenomics journal2018

Toxicogenomic module associations with pathogenesis: a network-based approach to understanding drug toxicity.

J J Sutherland, Y W Webster, J A Willy, G H Searfoss, K M Goldstein, A R Irizarry, D G Hall, J L Stevens

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in The pharmacogenomics journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Systematic comparison of temporal hepatotoxicant-induced gene network responses across 3 liver test systems.Toxicological sciences : an official journal of the Society of Toxicology · 2026
    Article
  3. Article
  4. Article
  5. AIVIVE: a novel AI framework for enhanced in vitro to in vivo extrapolation (IVIVE) of toxicogenomics data.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. AI-driven Discovery of Morphomolecular Signatures in Toxicology.bioRxiv : the preprint server for biology · 2024
    Article
  13. Review
  14. Article
  15. Article
  16. A systems approach reveals species differences in hepatic stress response capacity.Toxicological sciences : an official journal of the Society of Toxicology · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

J J SutherlandLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
Y W WebsterLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
J A WillyLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
G H SearfossLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
K M GoldsteinLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
A R IrizarryLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
D G HallLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
J L StevensLilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis IN, USA.
Eli Lilly (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite investment in toxicogenomics, nonclinical safety studies are still used to predict clinical liabilities for new drug candidates. Network-based approaches for genomic analysis help overcome challenges with whole-genome transcriptional profiling using limited numbers of treatments for phenotypes of interest. Herein, we apply co-expression network analysis to safety assessment using rat liver gene expression data to define 415 modules, exhibiting unique transcriptional control, organized in a visual representation of the transcriptome (the 'TXG-MAP'). Accounting for the overall transcriptional activity resulting from treatment, we explain mechanisms of toxicity and predict distinct toxicity phenotypes using module associations. We demonstrate that early network responses complement traditional histology-based assessment in predicting outcomes for longer studies and identify a novel mechanism of hepatotoxicity involving endoplasmic reticulum stress and Nrf2 activation. Module-based molecular subtypes of cholestatic injury derived using rat translate to human. Moreover, compared to gene-level analysis alone, combining module and gene-level analysis performed in sequence identifies significantly more phenotype-gene associations, including established and novel biomarkers of liver injury.

Indexed as

AnimalsDrug-Related Side Effects and Adverse ReactionsEndoplasmic Reticulum StressGene Expression ProfilingGene Expression RegulationGene Regulatory NetworksHumansLiverNF-E2-Related Factor 2PhenotypeRatsToxicogeneticsTranscriptomeNfe2l2 protein, ratNF-E2-Related Factor 2

Identifiers

PMID28440344
OpenAlexW2608029792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.